Cytotherapy

Article	Citations
Editorial Board	132
ESTABLISHING A NATIONAL REGULATORY POLICY AND FRAMEWORK FOR THERAPEUTIC USE OF CELL AND TISSUE THERAPIES IN SULTANATE OF OMAN.	87
CLINICALLY COMPLIANT MATRIX FOR HUMAN ES AND IPSC CULTURE FOR PRECLINICAL AND CLINICAL THERAPY	73
OPTIMIZATION OF AUTOMATED SELECTION AND LENTIVIRAL VECTOR MEDIATED TRANSDUCTION OF MSC	63
MICROPOROUS PARTICLE SCAFFOLDS FOR MESENCHYMAL STROMAL CELL EXPANSION AND ENHANCED IMMUNOMODULATORY FUNCTION	57
CARTAR WEB TOOL: A CASE STUDY UNVEILING PROMISING TARGETS FOR CHIMERIC ANTIGEN RECEPTOR THERAPIES IN COLORECTAL ADENOCARCINOMA	51
Aims and Scope	50
SAMPLE TYPE, BUT NOT STORAGE DURATION, IMPACTS POST-THAW CD34 VIABILITY ON CORD BLOOD UNITS	50
INVESTIGATING THE INTERPLAY BETWEEN GUT MICROBIOME, MONOCYTES/MACROPHAGES, AND OSTEOARTHRITIS	47
EFFECTS OF STORAGE TEMPERATURE ON VITAL PARAMETERS OF CLINICAL GRADE CRYOPRESERVED MESENCHYMAL STEM CELL FINAL PRODUCT	46
COMPARATIVE PROFILING OF MESENCHYMAL STEM CELL EXTRACELLULAR VESICLES FOR APPLICATION IN REGENERATIVE DERMATOLOGY	44
ECTOPIC EXPRESSION OF CD39, A KEY REGULATOR OF THE PURINERGIC SIGNALING PATHWAY, INCREASED THE IMMUNOMODULATORY PROPERTIES OF MSC-DERIVED EXTRACELLULAR VESICLES	40
Distinct effects of intravenous bone marrow-derived mesenchymal stem cell therapy on ischemic and non-ischemic lungs after ischemia-reperfusion injury	38
Predicting chimeric antigen receptor apheresis process volume	38
EFFICIENT COST-EFFECTIVE MANUFACTURE OF A NON-VIRAL TRANSPOSON BASED NOVEL BAFF-CART FOR TREATMENT OF B-CELL CANCERS	37
“Combined synergistic effects of concentrated growth factors and adipose-derived mesenchymal stem cells on regeneration of induced mandibular defects in rabbits”	36
Table of Contents	36
Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy	36
Editorial Board	35
Impact of Age and acute GVHD on Thymic Reconstitution Post-HCT: Insights from Multicenter Immune Monitoring of Pediatric and Young Adult Patients	35
The Impact of Prior Immunotherapy on Composition of Apheresis Material for CAR T-cell Therapy in Patients with B-Cell Acute Lymphocytic Leukemia (B-ALL)	32
MOUSE MESENCHYMAL STROMAL CELL POTENCY ASSAY IN CONTEXT OF USE IN ACUTE LUNG INJURY	31
Scalable Production of Hematopoietic Stem Cells and Microglia from iPSCs Using Stirred Tank Bioreactors for Consistent Cell Therapy Manufacturing	30
An innovative iPSC Reprogramming mRNA-LNP Kit for PBMC	29
Improving single cell multiomic analysis of T and B cells with innovations enhancing cost-effectiveness and data quality	28

CUTTING-EDGE LIPID-BASED MICROBUBBLE PLATFORM: ENHANCING CELL SORTING	27
The hyper-inflammatory ARDS microenvironment enhances MSC reparative capacity in a pre-clinical model of acute lung inflammation	27
A Narrative Review of Islamic Bioethics and Regenerative Medicine: The Case of Amniotic Fluid Mesenchymal Stem Cells	27
Classification of Foreign Materials Found in Mesenchymal Stem/Stromal Cell Product Manufacturing	27
ACOUSTIC BEADS: A NOVEL METHOD FOR CELL SORTING USING ACOUSTOPHORESIS	27
Evaluating CAR T cell therapy processing with the Sefia™ expansion system using commercially available cell culture media	26
Process Development and Manufacturing: IMPROVED DOWNSTREAM VIRUS PURIFICATION YIELD USING EXCIPIENT-GRADE RECOMBINANT ALBUMIN, EXBUMIN	25
Streamlined Production of Tumor-Associated Antigen-Specific T Cells (TAAT) from Antigen-Naïve Donors in a GREX Device Using Autologous Monocyte-Derived Dendritic Cells (MoDC) Manufactured in the Same	25
Elevating MSC-EV Analysis: Development and Qualification of a CD73 Bioactivity Assay	25
Thymic Regulatory NK Cells: A Therapeutic Target for Restoring Immune Balance in Chronic Graft-Versus-Host Disease (cGVHD).	25
CONSTRUCTION OF DEAD-CAS9 MACHINERY FOR ACTIVATION OF ENDOGENOUS NEUROPROTECTIVE TRANSCRIPTION FACTOR MAX IN VITRO	25
HYDROGEL MICROPARTICLE-BASED ARTIFICIAL ANTIGEN-PRESENTING CELL FOR EFFICIENT EXPANSION AND REACTIVATION OF NK CELLS EX VIVO.	25
Mesenchymal Stem/Stromal Cells: EVALUATION OF SCALABLE ATTACHMENT-DEPENDENT EXPANSION SYSTEM FOR MESENCHYMAL STEM CELLS IN XENO- AND SERUM-FREE MEDIA	24
Immunotherapy: MULTI-CENTER GAMMA-DELTA T CELL CLINICAL TRIAL PRODUCT IDENTIFICATION USING NEW PRODUCT ATTRIBUTE AND NEW CODES FOR ISBT 128 LABELING	24
Process Development and Manufacturing: CAR-T CELLS MANUFACTURED VIA POSITIVE AND NEGATIVE IMMUNOMAGNETIC T CELL SELECTION SHOW DIFFERENT TUMOR KILLING RATES, CYTOKINE PROFILES, AND γδ T CELL OUTPUT	24
A Simple Approach to Monitor the Cryostorage of Hematopoietic Stem Cells	24
Exosomes/EVs: REAL-TIME BIOPROCESS MONITORING FOR LARGE-SCALE PRODUCTION OF MESENCHYMAL STROMAL CELL-DERIVED EXTRACELLULAR VESICLES	24
GENERATION AND OPTIMIZATION OF ANTI-CD19 CAR-T CELL FOR LEUKEMIA IMMUNOTHERAPY	24
Mesenchymal Stem/Stromal Cells: DEVELOPMENT OF ICH Q2 (R1) COMPLIANT IMMUNOPOTENCY ASSAY MEASURING MESENCHYMAL STROMAL CELLS MEDIATED T-CELL INHIBITION	24
Marrow changes and reduced proliferative capacity of mesenchymal stromal cells from patients with “no-option” critical limb ischemia; observations on feasibility of the autologous approach from a clin	23
GENERATION OF HUMAN INDUCED PLURIPOTENT STEM CELL LINES DERIVED FROM TWO BRAZILIAN PATIENTS WITH HUTCHINSON-GILFORD PROGERIA SYNDROME CARRYING C.1824 C>T MUTATION	23
THERAPEUTIC BENEFIT OF HUMAN WHARTON’S JELLY MESENCHYMAL STROMAL CELLS IN A MOUSE MODEL OF AMYOTROPHIC LATERAL SCLEROSIS	23
Mesenchymal Stem/Stromal Cells: MULTIPOTENT MESENCHYMAL STROMAL CELLS FROM PATIENTS WITH SYSTEMIC SCLEROSIS HAVE PRESERVED CLONOGENICITY, IMMUNOPOTENCY AND IN VITRO ANTIFIBROTIC EFFECTS	22
Process Development and Manufacturing: A NEEDLE-BASED AUTOSAMPLER FOR BIOREACTOR CELL MEDIA COLLECTION	22
Aims and Scope	22
iPSC: ENGINEERING 3D MICRO-COMPARTMENTS FOR HIGHLY EFFICIENT AND SCALE-INDEPENDENT EXPANSION OF HUMAN PLURIPOTENT STEM CELLS IN BIOREACTORS	22
THE EFFECT OF THE PRO-APOPTOTIC RHTRAIL PROTEIN IN THE PRESENCE OR ABSENCE OF THE COMBINATION WITH THE HSV-1 VIRUS IN HEAD AND NECK TUMOR LINES	22
iPSC: IDENTIFICATION AND VALIDATION OF VENTRICULAR-SPECIFIC SURFACE MARKER FOR HUMAN PLURIPOTENT STEM CELLS-DERIVED CARDIOMYOCYTES	22
PREPARATION OF MUSCLE-DERIVED STEM CELLS SPHEROIDS IN A SCAFFOLD-FREE MICROMOLDED HYDROGEL MAINTAINING THEIR MYOGENIC POTENTIAL	22
Immunotherapy: A 3D VASCULARIZED MICROFLUIDIC MODEL OF THE TUMOUR MICROENVIRONMENT FOR ASSAYING PSC DERIVED CAR-T CELL FUNCTION	21
Process Development and Manufacturing: MINIMIZING PARTICULATE CONTAMINATION IN SINGLE-USE SYSTEMS FOR BIOPHARMACEUTICAL AND PHARMACEUTICAL INDUSTRIES	21
Embryonic, Organ and Other Tissue Specific Stem Cells: EXPLORING THE ANTI-TUMOR EFFECTS OF HUMAN WHARTON’S JELLY DERIVED MESENCHYMAL STEM CELL SECRETOME ON PANCREATIC DUCTAL ADENOCARCINOMA CELLS IN CO	21
Mesenchymal Stem/Stromal Cells: TRANSFECTION OPTIMIZATION FOR GENERATING CLINICAL GRADE IL-10 mRNA ENGINEERED MSCS	21
Mesenchymal Stem/Stromal Cells: CAN PRIMING APPROACHES IMPROVE THE IMMUNOREGULATORY CAPABILITY OF HUMAN WHARTON’S JELLY DERIVED MESENCHYMAL STEM CELLS TO TREAT PANCREATIC CANCER?	21
Welcome to ISCT 2023	20
Tissue Engineering: AUTOLOGOUS 3D NEURAL IMPLANTS FOR SPINAL CORD INJURY	20
Mesenchymal Stem/Stromal Cells: CELL CULTURE MEDIA (CCM) AND/OR LICENSING SIGNIFICANTLY AFFECTS THE GENE EXPRESSION, SECRETOME AND IMMUNE CELL INTERACTION CAPACITY OF UMBILICAL CORD DERIVED MESENCHYMA	20
Process Development and Manufacturing: ONE YEAR FROM VECTOR TO BEDSIDE: RAMPING UP A SUCCESSFUL IN-HOUSE CAR T-CELL MANUFACTURING PROGRAM USING A NOVEL TRI-SPECIFIC CAR T-CELL THERAPY FOR LYMPHOID MAL	20
Mesenchymal Stem/Stromal Cells: CELLULAR AGING SECRETES: A COMPARISON OF BONE MARROW DERIVED AND INDUCED MESENCHYMAL STEM CELLS AND THEIR SECRETOME OVER LONG TERM CULTURE	19
An International Society for Cell and Gene Therapy Mesenchymal Stromal Cells (MSC) Committee perspectives on International Standards Organization/Technical Committee 276 Biobanking Standards for bone	19
MESENCHYMAL STROMAL CELLS INFLUENCE THE EPIGENETIC LANDSCAPE OF TRAINED MACROPHAGES IN A CLINICALLY RELEVANT MODEL OF ALLERGIC ASTHMA	19
Editorial Board	19
A report on the International Society for Cell & Gene Therapy 2022 Scientific Signature Series, “Therapeutic advances with native and engineered human extracellular vesicles”	19
Programmed spontaneously beating cardiomyocytes in regenerative cardiology	19
ANALYSIS OF COLD CHAIN PROCESSES FOR INVESTIGATIONAL CELL THERAPY PRODUCT SHIPMENTS AND TRANSPORT BASED ON REAL-WORLD TEMPERATURE DATA	19
SAFETY AND EFFICACY RESULTS FROM A PHASE 1/2 CLINICAL TRIAL OF OCU400 MODIFIER GENE THERAPY FOR TREATMENT OF RETINITIS PIGMENTOSA	19
FAPα-TARGETED IMMUNOTHERAPY WITH SIBROTUZUMAB AND HIGH AFFINITY FC-RECEPTOR EXPRESSING NK92 CELLS: A PROMISING APPROACH TO REVERSE FIBROSIS	19
INTER-DONOR VARIABILITY AND CELLULAR PROLIFERATION: THEIR IMPACT ON THE IMMUNOMODULATORY STRENGTH OF ADIPOSE-DERIVED MESENCHYMAL STEM CELLS IN T CELL-MEDIATED HEPATITIS	19
FIXING THE FOUNDATION: A PROPOSED MODEL FOR CGT DEVELOPMENT	18
PHENOTYPIC CHANGES IN MESENCHYMAL STROMAL CELLS AND THEIR EXTRACELLULAR VESICLES DURING SERIAL PASSAGING	18

A NOVEL WORKFLOW TO EVALUATE, COMPARE, AND STANDARDIZE CELL VIABILITY ANALYTICS	18
CLOT FORMATION IN CELLULAR APHERESIS PRODUCTS: OCCURRENCE, RISK FACTORS AND MITIGATION	18
ROBUST AUTOMATED LEUKAPHERESIS CRYO-PROCESSING ENABLES HIGH-QUALITY STARTING MATERIAL FOR BOTH AUTOLOGOUS AND ALLOGENEIC CAR-T CELL THERAPY MANUFACTURING	18
ON-DEMAND HYDROGEL MICROCARRIER PRODUCTION BY INK-JET BIOPRINTING FOR STEM CELL LARGE-SCALE CULTIVATION	18
BRIDGING SCALE-UP TO TRANSPLANTATION: PLURIPOTENT STEM CELL-DERIVED PANCREATIC ISLET ENCAPSULATION IN EMULSION-GENERATED HIGH CONCENTRATION ALGINATE BEADS	18
CLINICAL IMPROVEMENT OF BELL’S PALSY AFTER SEQUENTIAL SECRETOME AND MESENCHYMAL STEM CELL THERAPY: A CASE REPORT	18
ATMP PATH2PATIENT: BUILDNING A REGIONAL ECOSYSTEM FOR CELL AND GENE THERAPY TRANSITION	17
SHIP1 DELETION ENHANCES CAR-NK CELL THERAPUETIC POTENTIAL IN DIFFUSE LARGE B CELL LYMPHOMA	17
DATA-DRIVEN APPROACH TO GROWING A CELL AND GENE THERAPY (CGT) LABORATORY: MEMORIAL SLOAN KETTERING CANCER CENTER (MSKCC) CELL THERAPY LABORATORY (CTL) EXPERIENCE.	17
OPTIMIZING IPSC AGGREGATE EXPANSION: NOVEL SOLUTIONS FOR MEDIA EXCHAGE IN PERFUSION BIOREACTOR CULTURE.	17
ASSESSMENT OF THE XIOGENIX ARES X20+ AS AN AUTOMATED FILL-FINISH SOLUTION FOR TUMOR-INFILTRATING LYMPHOCYTE THERAPY MANUFACTURING	17
FROM IPSC TO IMSC: TRANSCRIPTOMIC INSIGHTS INTO DIFFERENTIATION IN HUMAN AND EQUINE SPECIES AND COMPARISON WITH PRIMARY MSC	17
MSC-DERIVED ADIPOSE SPHEROIDS OFFER A SUPERIOR OPTION FOR POLARIZING MACROPHAGES TO AN ANTI-INFLAMMATORY PHENOTYPE	17
MSC-EVS AS IMMUNOMODULATORS OF B CELL ACTIVATION	17
PROBETILITY: A FIRST-IN-HUMAN PHASE I/IIA TRIAL OF REPEATED AUTOLOGOUS TUMOUR-INFILTRATING LYMPHOCYTE ADMINISTRATIONS IN METASTATIC COLORECTAL OR PROSTATE CANCER	17
A POPULATION HEALTH-BASED APPROACH TO INFORM THE PROVISIONING OF GENE THERAPIES FOR SEVERE SICKLE ANEMIA IN A LARGE, VERTICALLY INTEGRATED, VALUE-BASED HEALTH CARE SYSTEM	17
A NOVEL SEMI-DECENTRALIZED MANUFACTURING MODEL FOR SCALABLE, POTENT, OFF-THE-SHELF NK CELL THERAPY FOR CANCER AND AUTOIMMUNE DISEASES	16
Human cornea-derived mesenchymal stromal cells inhibit T cells through indoleamine 2,3 dioxygenase	16
Clinical trial assessing the safety and efficacy of human bone marrow-derived allogeneic mesenchymal stem cell therapy for chronic active antibody-mediated rejection in kidney transplant recipients	16
Safety and Efficacy of High-Dose Memory CD45RO+ Donor Lymphocyte Infusion in Pediatric Recipients after Hematopoietic Stem Cell Transplantation	16
Role of mesenchymal stromal cells derivatives in diabetic foot ulcers: a controlled randomized phase 1/2 clinical trial	16
2B4 inhibits the apoptosis of natural killer cells through phosphorylated extracellular signal-related kinase/B-cell lymphoma 2 signal pathway	16
A comprehensive review of quantum bioreactor cell manufacture: Research and clinical applications	15
Chimeric synthetic T cell receptor and antigen receptor receptors enable high-sensitivity T cell receptor-negative CD8αβ-CD3-positive T-cell development from human-induced pluripotent stem cells	15
Secretome of bone marrow mesenchymal stromal cells cultured in a dynamic system induces neuroprotection and modulates microglial responsiveness in an α-synuclein overexpression rat model	15
Regulatory advancements in Japan's conditional and time-limited approval scheme for regenerative medical products: the first guidance on the approval scheme and the second review for full approval of	14
Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragments	14
Enhancing Gene Transfer Efficiency in Viral and Non-Viral Vectors for Therapeutic Delivery	14
Proteomics profile of mesenchymal stromal cells and extracellular vesicles in normoxic and hypoxic conditions	14
Repeated intravenous doses of human umbilical cord-derived mesenchymal stromal cells for bronchopulmonary dysplasia: results of a phase 1 clinical trial with 2-year follow-up	14
Isolation of adipose-derived mesenchymal stem cells expressing soluble forms of GAS1 and PTEN for experimental cell therapy for glioblastoma	13
Initial Experience Implementing a Structured Review Service for Non-GLP Study Data Intended to Support Regulatory Submissions at an Academic Institution	13
Investigating MSC immune suppressive function with quantitative phase microscopy and single-cell spatial lipidomics	13
LONG-TERM TOLERANCE TO LEYDIG CELL TRANSPLANTATION WITH LOCALIZED TREG IMMUNOMODULATION USING THE NANOLYMPH PLATFORM	13
Haploidentical Transplantation versus Umbilical Cord Blood Transplantation in Acute Myeloid Leukemia with Measurable Residual Disease	13
Comparative Analysis of Advanced Therapy Regulatory Frameworks in Latin America: Perspectives from the ISCT South and Central America Legal and Regulatory Affairs Committee	13
Advancing CAR-NK Cell Engineering by Overcoming Transduction Challenges	13
Key Strategies for Successful Equipment Qualification in Cell Therapy GMP	13
Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity	13
International Society for Cell & Gene Therapy Expanded Access Working Group position paper: key considerations to support equitable and ethical expanded access to investigational cell- and gene-ba	13
Therapeutic Potential of First-Trimester Human Umbilical Cord Perivascular Cells in Mitigating Age-Related Muscle Dysfunction in a Natural Mouse Model of Aging	13
Advancing Wound Healing with Pre-Activated Umbilical Cord Mesenchymal Stem Cell Secretome	13
Particulate Management in Bioprocessing: Challenges, Strategies, and Solutions	13
EXPLORING INNOVATIVE BIOREACTOR SYSTEM FOR END-TO-END T CELL MANUFACTURING	12
ENEPC-CLI-01- A PHASE 2 DOUBLE BLIND PLACEBO CONTROLLED STUDY FOR AUTOLOGOUS BGC-101, ENRICHED ENDOTHELIAL PROGENITOR CELLS, FOR CRITICAL LIMB THREATENING ISCHEMIA	12
Scientific venturing for early-stage professionals (ESPs), a key concept in the innovation ecosystem	12
BACK TO BASICS: A SCIENTIFIC AND ECONOMIC EVALUATION OF ADHERENT AND SUSPENSION PROCESSING FOR AAV AT SCALE	12
Results of the Phase I/IIb EXCELLENT trial evaluating the safety and efficacy of transendocardial injection of expanded autologous CD34+ cells in patients with recent myocardial infarction	12
IMPROVED UNDERSTANDING OF CELL FATE USING A KIDNEY NORMOTHERMIC MACHINE PERFUSION MODEL	12
BIOMATERIAL-ENABLED MACROPHAGE CELL THERAPY VIA DEXAMETHASONE-LOADED MICROPARTICLES FOR REGENERATIVE MEDICINE	12
AUTOANTIGEN-SPECIFIC REGULATORY T CELLS HALT THE PROGRESSION OF LUPUS NEPHRITIS	12
AdoShell®, a non-fibrotic encapsulation system for cell delivery	12
Detection of very small embryonic-like stem cells (VSELs) in the peripheral blood of rabbits subjected to induced retinal vein occlusion as a proposed early detection tool for the disease	12
IMPLEMENTING CUSTOM PARTICLE SWARM-DIFFERENTIAL EVOLUTION OPTIMIZATION (PSODE) FOR GFP PLASMID DNA TRANSFECTION IN JURKAT AND PRIMARY T CELLS	12
THE MULTI POTENTIALS OF PLACENTA CHORIODECIDUAL MEMBRANES-DERIVED-MSCS (PCMSCS) FOR DECIDUALIZATION AND ANGIO-MYOGENESIS	11
NON-VIRAL GENOME EDITING IN HEMATOPOIETIC STEM CELLS (HSCS) FOR CELL-THERAPY APPLICATIONS - FROM DISCOVERY TO MANUFACTURING	11
BIOPOTENCY AND SURROGATE ASSAYS TO VALIDATE IMMUNOMODULATORY POTENCY OF EXTRACELLULAR VESICLES DERIVED FROM MESENCHYMAL STEM/STROMAL CELLS	11
Mesenchymal Stem/Stromal Cells: EVALUATION OF THE EFFECT OF MEDIUM COMPOSITION ON THE PHENOTYPIC AND FUNCTIONAL ATTRIBUTES OF MESENCHYMAL STROMAL CELLS	11
Immunotherapy: ANTI-GD2 CAR T CELLS AGAINST SMALL CELL LUNG CANCER	11
Immunotherapy: PHASE I CLINICAL TRIAL OF ANTI-MINOR HISTOCOMPATIBILITY ANTIGEN EXPANDED T CELLS TO TARGET LEUKEMIA RELAPSING AFTER ALLOGENEIC HLA-MATCHED TRANSPLANTATION	11
INSIGHTS INTO SPATIOTEMPORAL DYNAMICS OF ALLOREACTIVE T CELL RESPONSE WITH γMSCS ADMINISTRATION	11
A NEW ERA OF BIOLOGICS: THE ROLE OF SOUTH KOREA's REGULATORY SCIENCE CENTER IN ENSURING LONG TERM SAFETY	11
MULTIOMIC PROFILING OF EX VIVO EXPANDED CD45 (+)CD34(BRIGHT) CD38(-) CD90(+) CD49F(+)CELLS REVEALS NOVEL PATHWAYS FOR THE LONG-TERM MAINTENANCE OF HEMATOPOIETIC STEM AND PROGENITOR CELLS	11
Gene Editing/Gene Therapies: GDA-501 HER-2 CHIMERIC ANTIGEN RECEPTOR NATURAL KILLER CELLS: DUAL CYTOTOXICITY IN SOLID TUMORS MEDIATED VIA HER2 AND TRAIL	11
2023 Gene Therapy Mini-Series	11
Mesenchymal Stem/Stromal Cells: PATIENT RESPONSES TO MESENCHYMAL STROMAL CELL (MSC) THERAPY IN OSTEOARTHRITIS ARE ASSOCIATED WITH DIFFERENTIAL CLINICAL PHENOTYPES, MOLECULAR ENDOTYPES, AND MSC CRITICA	11
MANUFACTURE OF A BANK OF “OFF-THE-SHELF” CD30.CAR-EBVSTS FOR THE TREATMENT OF LYMPHOMA	11
MESENCHYMAL STROMAL CELLS EXPRESSING DEGRON-HPV16 E5 AS A NOVEL CERVICAL CANCER VACCINE	11
ABSOLUTE QUANTIFICATION OF GENOMIC TARGETS FOR CELL COUNTING USING DROPLET DIGITAL PCR	11
Mesenchymal Stem/Stromal Cells: UPFRONT USE OF ALLOGENEIC CYTO-MSC IMPROVES RESPONSE AND SURVIVAL RATES IN PATIENTS WITH ACUTE GVHD: AN INTERIM ANALYSIS OF ONGOING PHASE I/II MULTICENTER CLINICAL STUD	11
Process Development and Manufacturing: SUPERIOR EXPANSION OF γδ T-CELL SUBSETS FOR SOLID TUMOR T-CELL THERAPY USING A CHEMICALLY-DEFINED NON-ANIMAL ORIGIN SERUM-FREE CULTURE MEDIUM	11
Regulatory Affairs, Quality Systems, Policy, and Ethics: EVALUATION OF PERCENTAGE CHANGE IN PRE-DONATION AND POST-DONATION LABORATORY VALUES AFTER REPEATED (MNC), APHERESIS DONATIONS	10
iPSC: THE IPS DERIVED MESENCHYMAL STEM CELLS AMELIORATED LIVER FIBROSIS AND LIVER FATTY DEPOSITION IN NAFLD/MAFLD-RELATED CIRRHOTIC MICE	10
Prognostic factors in haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia	10
Challenging immunophenotyping of patients with sickle cell disease adversely affects gene therapy product manufacturing – case reports.	10
Mesenchymal Stem/Stromal Cells: CELL CERAMTM ASSOCIATED WITH HUMAN LEVATOR VELI PALATINI MUSCLE STROMAL CELLS TO BONE RECONSTRUCTION IN CRANIOFACIAL SYNDROMES	10
IMMUNOMODULATORY POTENTIAL OF EXTRACELLULAR VESICLES DERIVED FROM MESENCHYMAL STEM CELLS OBTAINED BY ULTRAFILTRATION AND ULTRACENTRIFUGATION	10
Mesenchymal Stem/Stromal Cells: THE INTERFERON-GAMMA-INDOLEAMINE 2,3-DIOXYGENASE 1 (IFN-G-IDO1) AXIS IS NOT INVOLVED IN THE MSC-MEDIATED IMMUNOSUPPRESSION OF ACTIVATED T CELL PROLIFERATION	10
Mesenchymal Stem/Stromal Cells: HUMAN MESENCHYMAL STEM CELL THERAPY IN SEVERE COVID-19 PATIENTS: 2-YEAR FOLLOW-UP RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL	10
Mesenchymal Stem/Stromal Cells: EFFECTS OF COLD STORAGE ON MITOCHONDRIAL BIOENERGETICS AND PROTEIN IN HUMANMSCS	10

Gene Editing/Gene Therapies: A NOVEL WEIGHT-BASED APPROACH TO DETERMINE CELL TYPE SPECIFICITY FROM SINGLE CELL DATASETS	10
Gene Editing/Gene Therapies: ENHANCING ANTI-OXIDATION OF MESENCHYMAL STROMAL/STEM CELLS USING CRISPR/CAS9 FOR INFLAMMATORY AND ISCHEMIC-REPERFUSION INJURY	10
The peril of the promise of speculative cell banking: Statement from the ISCT Committee on the Ethics of Cell and Gene Therapy	10
Immunotherapy: CONVERTING IMMUNOLOGICALLY “COLD” MICROSATELLITE-STABLE COLORECTAL CANCER TO “HOT” BY DNA METHYLTRANSFERASE INHIBITOR AND RADIATION TO ENHANCE THERAPEUTIC EFFICACY	10
Subscription information	10
Mesenchymal Stem/Stromal Cells: SINGLE-CELL TRANSCRIPTOMICS COMPARISON OF CELL THERAPEUTICS IN OSTEOARTHRITIS	10
The donor genetic determinant of human thymopoiesis rs2204985 is associated with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients	10
Subscription information	10
Tissue Engineering: DEVELOPMENT OF A TISSUE-ENGINEERED PRODUCT FOR GINGIVAL RECESSION	10
Immunotherapy: THE BTLA-HVEM AXIS IS A CRUCIAL IMMUNE CHECKPOINT OF T CELL IMMUNOTHERAPIES FOR CANCER	10
IDENTIFICATION AND CHARACTERIZATION OF NOVEL VIRAL OPEN READING FRAMES	9
INTEGRATED TARGETED DELIVERY AND PLURIPOTENT STEM CELL–DERIVED THERAPIES FOR REGENERATIVE MEDICINE	9
VIVOCELL: AN ACCESSIBLE DELIVERY SYSTEM WITH PROVEN EFFICACY FOR IN VIVO ENGINEERING OF T CELLS	9
TARGETING MICROGLIAL P2X7R USING NON-VIRAL SIRNA DELIVERED VIA AN INJECTABLE HYDROGEL AS A TREATMENT FOR DRUG-REFRACTORY TEMPORAL LOBE EPILEPSY	9
COST-EFFECTIVE MESENCHYMAL CELL EXPANSION USING CORNING CELLCUBE SYSTEMS AS A PRECURSOR TO LARGE-SCALE PRODUCTION	9
DACS: A BUOYANCY-BASED PLATFORM FOR INTEGRATED T CELL SORTING AND ACTIVATION IN CELL THERAPY MANUFACTURING	9
ADVANCING MRNA THERAPEUTICS: LIPID NANOPARTICLES ENABLE SAFE AND EFFICACIOUS RNA LNP DELIVERY FOR REPEATED MRNA ADMINISTRATIONS IN NORMAL AND TUMOR-BEARING MICE.	9
ENGINEERING HUMAN PLATELET LYSATE-DERIVED EXTRACELLULAR VESICLES WITH TUMOR TARGETING PEPTIDE P28 FOR ENHANCED BREAST CANCER CELL UPTAKE	9
5-DAY NON-VIRAL CAR-T MANUFACTURING VIA ELECTROPORATION: PRESERVING POTENCY WHILE COMPRESSING TIMELINES	9
AUTOMATED GMP MANUFACTURING OF CYTOKINE-ACTIVATED NATURAL KILLER CELLS PRODUCES A POTENT AND SAFE CELL THERAPY PRODUCT FOR AML AND NEUROBLASTOMA	9
HUMAN MARROW-ISOLATED ADULT MULTILINEAGE INDUCIBLE CELLS-DERIVED EXTRACELLULAR VESICLES (MIA-EVS) EXHIBIT A CONDITIONING-RESISTANT MIRNA REGULATORY BACKBONE AND ENHANCED REGENERATIVE AND IMMUNOMODULAT	9
BIOMANUFACTURING ARCHITECTURE STABILIZES MSC OUTPUT AND PROGRAMS EXTRACELLULAR VESICLE POTENCY IN VIVO	9
INFUSION PRODUCT INFLAMMATORY SIGNATURES PREDICT ICANS BUT NOT EARLY RESPONSE AFTER CD19 CAR-T	9
IMPLEMENTING A STABILITY-BASED EXPIRY STRATEGY FOR CRYOPRESERVED HEMATOPOIETIC PROGENITOR CELLS: REAL-WORLD EXPERIENCE FROM AN INDIAN TRANSPLANT CENTER	9
DEVELOPMENT OF A NOVEL MEDIUM THAT FACILITATE SCALABLE SUSPENSION CULTURE OF PLURIPOTENT STEM CELLS TOWARD CLINICAL USE	9
ALLOGENEIC OSTEOBLAST THERAPY COMBINED WITH CORE DECOMPRESSION FOR OSTEONECROSIS OF THE FEMORAL HEAD	9
EXTRACELLULAR VESICLES DERIVED FROM CLONALLY-EXPANDED IMMORTALIZED MESENCHYMAL STROMAL CELLS REDUCE PERIPHERAL AND NEUROINFLAMMATION IN PRE-CLINICAL SEPSIS	8
THE ASSESSMENT OF WOMEN'S EDUCATION IN MEXICO ON CORD BLOOD (CB) BANKING AND ETHICAL IMPLICATIONS	8
Strategic infection prevention after genetically modified hematopoietic stem cell therapies: recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee	8
Yeast surface display meets immunotherapy: unlocking the potential of T cells	8
Real World Experience of a Single-Center Tumor Infiltrating Lymphocyte (TIL) Melanoma Therapy Program: primary referral to TIL infusion (Brain to Vein)	8
Allogeneic transplantation after immunotherapy for relapsed/refractory non-Hodgkin lymphoma: a comparison with a historical cohort	8
Dual-CAR NK cells targeting PD-L1 and ErbB2/HER2 eliminate solid tumor cells and prevent immune escape due to antigen loss	8
Graft-versus-host disease is associated with skewed γδ T-cell clonality after umbilical cord blood transplantation in children with nonmalignant diseases	8
Impact of mesenchymal stromal/stem cell infusions on circulating inflammatory biomarkers in COVID-19 patients: analysis of a phase I-IIa trial	8
Advanced therapies require soft skills: insights from a National Academies Working Group	8
GENE THERAPY FOR RECOMBINASE DEFICIENT-SCID	8
Increasing access to transplantation through telemedicine and patient navigation	8
PROCESS DEVELOPMENT FOR SCALABLE ALLOGENEIC CAR-T MANUFACTURING IN STIRRED-TANK BIOREACTORS: PERFUSION OPTIMISATION, MULTI-LITRE SCALE-UP AND AUTOMATED HARVESTING	8
MICROFLUIDICS IMPROVES LENTIVIRUS TRANSDUCTION EFFICIENCY	7
Accelerating sterility testing: Symcel calScreener+ achieves results in <3 days with direct inoculation in non-destructive and continuous monitoring system	7
CD73 activity of mesenchymal stromal cell-derived extracellular vesicle preparations is detergent-resistant and does not correlate with immunomodulatory capabilities	7
Outcomes following hematopoietic cell transplantation for children, adolescents and young adults with relapsed acute lymphoblastic leukemia	7
Impact of lower concentrations of dimethyl sulfoxide on cryopreservation of autologous hematopoietic stem cells: a systematic review and meta-analysis of controlled clinical studies	7
COMPARATIVE CHARACTERIZATION OF HUMAN DERMAL MESENCHYMAL STROMAL CELLS FROM DIFFERENT ANATOMICAL LOCATIONS AND ACROSS THE LIFESPAN	7
INKT-BASED CELLULAR PRODUCT FOR THE PREVENTION OF GVHD	7
AGING OF MESENCHYMAL STEM CELLS IN VITRO: IMPLICATIONS IN PHENOTYPE AND DIFFERENTIATION CAPACITY	7
Label-free, single-cell quantification of granulocyte macrophage progenitors from brightfield imaging	7
Integrating cell confinement in a perfusion bioreactor improves iMSC extracellular vesicle production and potency	7
SMART sensors for cell growth monitoring in closed system G-Rex for scalable, cost-conscious cell and gene therapy manufacturing	7
DNMT INHIBITOR-BASED EPIGENETIC MODULATION DURING MANUFACTURING ENHANCES CAR T-CELL FUNCTION AND PERSISTENCE IN PEDIATRIC BRAIN TUMORS	7
The emerging promise of induced pluripotent stem cells in clinical studies: a systematic scoping review of the literature and registered clinical trials	7
Filling the gap: the workforce of tomorrow for CGT manufacturing as the sector advances	7
A Multi-Donor Characterization of Degradable Microscaffolds for Therapeutic T Cell Manufacturing	7
EFFECTS OF IGF-1-OVEREXPRESSING MESENCHYMAL STROMAL CELL TRANSPLANTATION IN A MOUSE MODEL OF AMYOTROPHIC LATERAL SCLEROSIS	7
ACTIVATION, EXPANSION, AND CULTURE OF HUMAN T CELLS INCORPORATING IMMUNOCULTTM CGMP-COMPLIANT ANCILLARY REAGENTS	7
MULTIOMIC ANALYSIS OF γMSC-SUPPRESSED ALLOREACTIVE T CELLS	7
IMMUNOMODULATORY ROLE OF MESENCHYMAL STEM CELL-DERIVED EXTRACELLULAR VESICLES ON DENDRITIC CELLS	7
Subscription information	7
A machine-learning model that incorporates CD45 surface expression predicts hematopoietic progenitor cell recovery after freeze–thaw	7
INVESTIGATING THE ADVANCEMENTS IN MESENCHYMAL STEM CELLS AND THEIR SECRETOME: UNVEILING THE POTENTIAL FOR FACIAL REJUVENATION	7
STERILITY SAMPLING OF CELL, GENE, AND TISSUE THERAPY PRODUCTS (ATMPs)	7
IMMUNOMODULATORY POTENTIAL OF ENHANCED MSC-DERIVED EXTRACELLULAR VESICLES	7
Mesenchymal stromal cells regulate THP-1–differentiated macrophage cytokine production by activating Akt/mammalian target of rapamycin complex 1 pathway	7
Three-dimensional cell culture of chimeric antigen receptor T cells originated from peripheral blood mononuclear cells towards cellular therapies	7
PRE-CLINICAL CHARACTERIZATION OF ALLOCETRATM; A NOVEL MACROPHAGE REPROGRAMMING CELL THERAPY, FOR INTRA-ARTICULAR TREATMENT IN OSTEOARTHRITIS	7
The imperative to investigate epigenetic and transcriptional fidelity in long-term cryopreserved hematopoietic stem and progenitor cells	7
ICAM-1 KNOCK OUT HYPOIMMUNE PLURIPOTENT STEM CELL THERAPIES FOR CARDIOVASCULAR DISEASE AND TYPE 1 DIABETES	7
OPTIMIZING CHEMICALLY DEFINED CULTURE SYSTEMS FOR GMP-COMPLIANT PRODUCTION OF MESENCHYMAL STROMAL CELL–DERIVED EXTRACELLULAR VESICLES	7
A METHOD TO CLASSIFY MESENCHYMAL STEM/STROMAL CELLS BASED ON THEIR THERAPEUTIC POTENTIAL	7
Ex-vivo expanded CD34+ cell transplantation alleviates fibrotic liver injury via innate immune modulation in metabolic dysfunction-associated steatohepatitis mice	7
A PLATFORM FOR THE ISOLATION AND CHARACTERIZATION OF EXTRACELLULAR VESICLES - EXPLORING A COMPREHENSIVE COLLECTION OF HUMAN EV	7
MSC-ENABLED TWIN BITE IMMUNOTHERAPY TO OVERCOME GLIOBLASTOMA HETEROGENEITY	6
INTEGRATED CAR DESIGN OPTIMIZATION AND MYELOID REPROGRAMMING ENHANCE B7H3 CAR T CELL EFFICACY IN GROUP 3 MEDULLOBLASTOMA	6
Mesenchymal Stem/Stromal Cells: ROLE OF REACTIVE OXYGEN SPECIES IN SUPPRESSION OF ALLOREACTIVE T-CELLS BY INTERFERON-GAMMA PRIMED-MESENCHYMAL STROMAL CELLS	6
Immunotherapy: UTILIZATION OF BIDIRECTIONAL PROMOTERS IN SLEEPING BEAUTY-BASED DUAL CHIMERIC ANTIGEN RECEPTOR T CELL	6
CHARACTERIZATION OF CANINE UMBILICAL CORD MESENCHYMAL STEM CELLS	6
Mesenchymal Stem/Stromal Cells: THE IMPORTANCE OF CHEMICALLY-DEFINED MEDIA IN HAIR FOLLICLE CELL CULTURE FOR HAIR LOSS CELL THERAPY	6
Process Development and Manufacturing: EFFECT OF DONOR AND METHOD VARIABILITY ON BIOMANUFACTURING PROCESS ESTABLISHMENT	6
TESTING BATCH TO BATCH VARIABILITY OF HUMAN PLATELET LYSATE AS A MEDIUM SUPPLEMENT FOR GMP-COMPATIBLE SKELETAL CELL CULTURE	6
MUSE CELLS PROVIDE A CELL-THERAPY–BASED APPROACH TO COMBAT AMR CLINICAL PATHOGENS IN VITRO	6
Mesenchymal Stem/Stromal Cells: LOCAL MANUFACTURING PROCESSES CONTRIBUTE TO VARIABILITY IN HUMAN MESENCHYMAL STROMAL CELL (MSC) EXPANSION WHILE GROWTH MEDIA SUPPLEMENTS CONTRIBUTE TO VARIABILITY IN GE	6
Tissue Engineering: AUTOFLUORESCENCE IMAGING IDENTIFIES KEY SUBSTRATE PROPERTIES TO SUPPORT STEM CELL-DERIVED CARDIOMYOCYTE DIFFERENTIATION	6
Mesenchymal Stem/Stromal Cells: EXTRACTS FROM CHLORELLA VULGARIS PROTECT MESENCHYMAL STROMAL CELLS FROM OXIDATIVE STRESS INDUCED BY HYDROGEN PEROXIDE	6
CHARACTERIZATION AND EVALUATION OF GENETIC STABILITY OF URINE-DERIVED STEM CELLS	6
Mesenchymal Stem/Stromal Cells: COMPARISON ON THE CURATIVE EFFECTS OF MESENCHYMAL STEM CELL TRANSPLANTATION AND LOW-DOSE INTERLEUKIN-2 TREATMENT ON SYSTEMIC LUPUS ERYTHEMATOSUS	6
Process Development and Manufacturing: C3P3-G3 ARTIFICIAL EXPRESSION SYSTEM FOR HIGH PERFORMANCE LENTIVIRUS PRODUCTION WITH IMPROVED PREDICTED BIOSAFETY	6
JURISDICTIONAL LOOPHOLES IN ACCELERATED REGULATORY SCHEMES DRIVE UNSAFE STEM CELL TOURISM ACROSS THE APAC REGION	6
BRIDGING R&D AND GMP MANUFACTURING THROUGH SCALABLE, AUTOMATED CELL THERAPY PRODUCTION USING THE SOLUPORE® INTEGRATED PLATFORM	6
MICROBIOLOGICAL QUALITY CONTROL OF HMSC ATMPS: VALIDATION OF STERILITY AND ENDOTOXIN ASSAYS	6
Immunotherapy: NK CELL EXPANSION USING SCALE UP BIOREACTORS FOR CELL THERAPY	6
Regulatory Affairs, Quality Systems, Policy, and Ethics: VALIDATION AND COMPARISON OF AEROBIC AND ANAEROBIC BACTERIA, YEAST AND MOULD DETECTION USING THE BACT/ ALERT® 3D™ AND VIRTUO™ SYSTEMS FOR HAEMA	6
Mesenchymal Stem/Stromal Cells: TRANSCRIPTOMIC ANALYSIS OF HUMAN MESENCHYMAL STEM CELLS FROM UMBILICAL CORD EXPANDED WITH INACTIVATED GMP-GRADE HUMAN PLATELET LYSATE	6
VIABILITY, DIFFERENTIATION PROFILE AND GENIC EXPRESSION OF UMBILICAL CORD BLOOD HEMATOPOIETIC PROGENITOR CELLS CULTURED ON PLA/COL/HA/MSC-WJ CONSTRUCTS AS AN EX VIVO EXPANSION STRATEGY	6
Immunotherapy: IMPROVING CAR T CELL EFFICACY IN A PRECLINICAL MODEL OF BREAST CANCER THROUGH MODIFIED MANUFACTURING METHODS AND ADJUVANT THERAPY	6